FDA to Sarepta: This is what we really meant
This article was originally published in Scrip
Executive Summary
One need only to look at the language the FDA used in a 30 October evening statement about its efforts to communicate with Sarepta Therapeutics about its experimental Duchenne muscular dystrophy (DMD) drug eteplirsen to see how exasperated the agency appears.